Crysvita
Payments companies reported to CMS as associated with Crysvita. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Crysvita, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Crysvita
These are the largest totals companies reported as associated with Crysvita. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Anthony Portale | San Francisco, CA | Pediatrics | $127,781.61 |
| Joshua Yang | Orlando, FL | Pediatric Endocrinology | $90,983.86 |
| Nancy Dunbar | Farmington, CT | Pediatric Endocrinology | $75,023.46 |
| Eric Rush | Kansas City, MO | Clinical Genetics (M.D.) | $74,424.41 |
| Surya Mulukutla | Edinburg, TX | Endocrinology, Diabetes & Metabolism | $62,924.80 |
| Laila Tabatabai | Houston, TX | Endocrinology, Diabetes & Metabolism | $53,657.70 |
| Edward Lewiecki | Albuquerque, NM | Internal Medicine | $52,191.88 |
| Charles Mckay | Charlotte, NC | Pediatric Nephrology | $47,558.04 |
| Michael Assayag | Baltimore, MD | Orthopaedic Surgery | $43,044.76 |
| Suzanne Jan De Beur | Charlottesville, VA | Endocrinology, Diabetes & Metabolism | $38,149.94 |
Prescribed Crysvita?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.